Search Results
Oct 01, 2025, 06:00 ET PhotonPharma Inc. CEO to Present Novel Autologous Treatment Platform at Premier Cancer Immunotherapy Conference
from industry leaders including Moderna, Merck, BioNTech, and Genentech, alongside innovative companies developing next-generation platforms across mRNA, peptide, viral, and cellular modalities. About PhotonPharma PhotonPharma
More news about: PhotonPharma Inc.
Sep 29, 2025, 10:18 ET METiS Launches World's First AI-Driven Nano-Delivery Platform NanoForge
infrastructure and predictive accuracy. Built on this platform are three core solutions: AiLNP (AI Nucleic Acid Delivery Design), AiRNA (AI mRNA Sequence Design), and AiTEM (AI Small Molecule Formulation Design). To date, METiS has built a library of over 10 million
More news about: METiS TechBio
Sep 26, 2025, 11:00 ET Factor Bioscience Files Complaint Against Cellectis and AstraZeneca Alleging Infringement of Foundational Gene-Editing Patents
In the complaint, Factor alleges that Cellectis transformed its research program after learning about Factor's patented mRNA TALENs technology in 2013 and proceeded to illegally exploit that technology, including in its partnership with AstraZeneca, by infringing Factor's
More news about: Factor Bioscience Inc.
Sep 25, 2025, 08:00 ET Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
market value CAR-T company, will share the story of Legend's success. Latest Progress and Future Outlook in Gene Therapy and mRNA Gene therapy and mRNA technologies have moved from promise to practice, delivering clinical milestones in both rare diseases and broader indications. Yet
More news about: GenScript Biotech Corporation
Sep 24, 2025, 10:00 ET 15th Annual Nikon Small World in Motion Competition Winner Magnifies Self-Pollination Process in a Common Wildflower
Oxford, Oxfordshire, United Kingdom Delivery of a synthetic mRNA to cultured HeLa cellsSpinning Disk Confocal 60X (Objective Lens Magnification) Dr. Ziwen He & Min
More news about: Nikon Instruments Inc.
Sep 24, 2025, 07:30 ET Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000
existing mRNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved therapeutic index. RBI-4000, the company's clinical-stage srRNA rabies vaccine, has demonstrated protective levels of immunity at doses lower than any other reported mRNA or srRNA
More news about: Replicate Bioscience
Sep 23, 2025, 10:30 ET Nanoparticle Based Vaccines to Treat, Prevent Severe Allergic Reactions
Weissman, who was awarded a Nobel Prize in 2023 for his contributions to the mRNA technology that led to the first effective COVID vaccines. In this application, the research team attached specific allergy-related mRNA strands to nanoparticles derived from lipids. Each nanoparticle is about 50
More news about: Cincinnati Children's Hospital Medical Center
Sep 22, 2025, 21:41 ET GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea
targeting infected cells. GC4006A is the key product of the mRNA-LNP(Lipid Nanoparticle) platform that the company has developed through its mRNA-LNP research since 2019. This platform enables the company to manage the entire mRNA vaccine development process end-to-end. The upcoming Phase 1 clinical
More news about: GC Biopharma
Sep 22, 2025, 11:16 ET RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence
Pfizer Pfizer remains a dominant force in mRNA vaccines, generating US$ 25 billion in 2024 from its COVID-19 and pipeline vaccines. The company is actively advancing oncology-focused mRNA vaccines in partnership with biotech firms. Moderna
More news about: DataM Intelligence 4 Market Research LLP
Sep 17, 2025, 17:09 ET MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.
biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical data of an mRNA-lipid nanoparticle (mRNA-LNP) based in vivo CAR T candidate, HN2301, in The New England Journal of Medicine. The study, titled "In vivo CD19-CAR T-Cell Therapy
More news about: Shenzhen MagicRNA Biotech Co., Ltd.
Sep 17, 2025, 08:47 ET Frame Bio Licenses Novel Drug Delivery Technology from Mercury Bio to Develop Regenerative Therapies for Bone and Collagen Diseases and Disorders
structural inflammation and pain. Initially, both the bone regeneration and collagen regeneration therapies are being designed for direct delivery of mRNA payloads to the wound or pain site, and will remain in the pre-clinical research phase for the year ahead. At the same time, Frame Bio intends to continue
More news about: Frame Bio LLC
Sep 17, 2025, 08:00 ET Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
with 62% lowering at Day 84 on the 9mg daily oral dose Additional findings include dose-dependent reductions in PMS1 mRNA, excellent brain penetration, and a favorable safety profile SKY-0515's Phase 2/3 FALCON-HD trial in patients in Australia
More news about: Skyhawk Therapeutics
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
(2) MBNL sequestration in toxic DMPK mRNA, which leads to a spliceopathy, and is the cause of symptomatology in DM1 patients. By inhibiting miR-23b, ARTHEx has demonstrated that ATX-01 increases MBNL production and decreases foci formation and toxic DMPK mRNA. This highly differentiated dual mechanism
More news about: ARTHEx Biotech
Sep 15, 2025, 16:30 ET WesternU researchers show Osteopathic Manipulative Treatment improves efficacy of COVID-19 vaccine
Joseph Zammuto, Sir Robert Hostoffer, Jesus Sanchez. COVID-19 mRNA vaccine immune response to the addition of osteopathic manipulative treatment with lymphatic pumps: a randomized controlled trial. Virus Research, Volume
More news about: Western University of Health Sciences
Sep 15, 2025, 09:02 ET ISPE Announces its 2025 ISPE Annual Meeting & Expo Keynote Speakers
Excellence: Takeda's Quality Transformation," presented by Elaine Shannon, Global Quality Officer, Takeda"Scaling mRNA Impact Through Platform, Culture, and Digital," presented by Jerh Collins, PhD, Chief Technology Operations and Quality Officer, Moderna"Crisis
More news about: ISPE
Sep 15, 2025, 08:30 ET Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
reporting positive phase 2 interim results in people with OTC deficiency treated with ARCT-810, an mRNA therapeutic candidate. ARCT-810 is designed to replace the OTC enzyme and restore urea cycle activity preventing hyperammonemia crises. "We are very
More news about: NetworkNewsWire
Sep 15, 2025, 08:00 ET Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
Engineered with optimized GalNAc-conjugated delivery and chemical modifications, it minimizes off-target risks and demonstrated more than 90% INHBE mRNA knockdown in monkeys with a low single dose. RN3161's long-lasting gene silencing supports Q6M to Q12M dosing, enhancing patient adherence and suitability
More news about: Rona Therapeutics
Sep 15, 2025, 08:00 ET Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity
Engineered with optimized GalNAc-conjugated delivery and chemical modifications, it minimizes off-target risks and demonstrated more than 90% INHBE mRNA knockdown in monkeys with a low single dose. RN3161's long-lasting gene silencing supports Q6M to Q12M dosing, enhancing patient adherence and suitability
More news about: Rona Therapeutics
Sep 15, 2025, 08:00 ET Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
diseases," said Dr. Dongxu Shu, co-founder and CEO of Argo Biopharma. BW-40202 is an siRNA therapeutic that targets CFB mRNA in the liver. It utilizes an RNA interference (RNAi) mechanism to suppress CFB expression, thereby reducing serum CFB protein levels and inhibiting
More news about: Argo Biopharmaceutical Co., Ltd.
Sep 14, 2025, 20:00 ET Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
treatments for serious conditions addressing unmet medical needs. LioCyx-M004 represents an innovative autologous cell therapy engineered using mRNA to encode T-cell receptors that specifically target hepatitis B virus antigens. Preclinical and early clinical studies have demonstrated the therapy's
More news about: Lion TCR